Arbutus Biopharma Corp financial data

Symbol
ABUS on Nasdaq
Industry
Pharmaceutical Preparations
Location
701 Veterans Circle, Warminster, PA
State of incorporation
British Columbia, Canada
Fiscal year end
December 31
Former names
TEKMIRA PHARMACEUTICALS CORP (to 8/3/2015), TEKMIRA PHARMACEUTICALS Corp (to 8/3/2015)
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 703 % +13.5%
Debt-to-equity 32 % -3.56%
Return On Equity -63.4 % -9.6%
Return On Assets -48 % -10.6%
Operating Margin -1.24K % -187%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 191M shares +1.46%
Common Stock, Shares, Outstanding 190M shares +11.8%
Entity Public Float 454M USD +57.7%
Common Stock, Value, Issued 1.41B USD +4.46%
Weighted Average Number of Shares Outstanding, Basic 186M shares +11.8%
Weighted Average Number of Shares Outstanding, Diluted 186M shares +11.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 6.17M USD -66%
Research and Development Expense 54M USD -26.7%
General and Administrative Expense 22.1M USD -1.63%
Operating Income (Loss) -76.3M USD +2.28%
Nonoperating Income (Expense) 6.4M USD +21.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20.1M USD -14.4%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -69.9M USD +4.02%
Earnings Per Share, Basic -0.38 USD/shares +13.6%
Earnings Per Share, Diluted -0.38 USD/shares +13.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.3M USD +38.2%
Cash, Cash Equivalents, and Short-term Investments 123M USD -7.33%
Accounts Receivable, after Allowance for Credit Loss, Current 2.41M USD +35.6%
Assets, Current 127M USD -3.57%
Property, Plant and Equipment, Net 3.31M USD -29.2%
Operating Lease, Right-of-Use Asset 1.05M USD -26%
Other Assets, Noncurrent 34K USD
Assets 132M USD -8.79%
Liabilities, Current 15.6M USD -30.5%
Operating Lease, Liability, Noncurrent 806K USD -40%
Liabilities 34.3M USD -10.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -48.1M USD +0.59%
Retained Earnings (Accumulated Deficit) -1.35B USD -5.48%
Stockholders' Equity Attributable to Parent 97.4M USD -8.16%
Liabilities and Equity 132M USD -8.79%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.3M USD +29.3%
Net Cash Provided by (Used in) Financing Activities 24.4M USD +19.7%
Net Cash Provided by (Used in) Investing Activities 11.7M USD -29.9%
Common Stock, Shares, Issued 190M shares +11.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 16.8M USD +71.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36.3M USD +38.2%
Deferred Tax Assets, Valuation Allowance 175M USD +7.16%
Operating Lease, Liability 1.29M USD -27.1%
Payments to Acquire Property, Plant, and Equipment 95K USD -18.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -69.6M USD +1.62%
Lessee, Operating Lease, Liability, to be Paid 1.42M USD -30.3%
Property, Plant and Equipment, Gross 16.3M USD -1.62%
Operating Lease, Liability, Current 483K USD +13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 654K USD +2.99%
Lessee, Operating Lease, Liability, to be Paid, Year One 634K USD +2.92%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 133K USD -50.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 134K USD -79.5%
Deferred Tax Assets, Operating Loss Carryforwards 96.1M USD +7.84%
Preferred Stock, Shares Authorized 1.16M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Additional Paid in Capital 82M USD +0.96%
Depreciation, Depletion and Amortization 355K USD +6.29%
Share-based Payment Arrangement, Expense 8.99M USD -3.39%
Interest Expense 168K USD -84.8%